It is advised that, in the future, two main research aims should be sought: (A) Longer follow-up should clear the question whether sarcopenia and frailty, according to FRAIL and ALT assessments, are also indicative of worse, long-term clinical outcomes (such as 5-years survival). This evidence concerns the gene GPT and sarcopenia.